Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate

被引:12
作者
Scarpazza, Cristina [2 ]
Signori, Alessio [3 ]
Cosottini, Mirco [4 ]
Sormani, Maria Pia [3 ]
Gerevini, Simonetta [5 ]
Capra, Ruggero [1 ]
机构
[1] ASST Spedali Civili Brescia, Reg Multiple Sclerosis Ctr, Via Ciotti 154, I-25018 Brescia, Italy
[2] ASST Spedali Civili Brescia, Reg Multiple Sclerosis Ctr, Montichiari, Italy
[3] Univ Genoa, Dept Hlth Sci, Genoa, Italy
[4] Univ Pisa, Dept Translat Res & New Surg & Med Technol, Pisa, Italy
[5] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neuroradiol, Milan, Italy
关键词
Natalizumab; progressive multifocal leukoencephalopathy; lesion volume; high frequency MRI; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; MULTIPLE-SCLEROSIS; HIGHER RISK; ASYMPTOMATIC PML; RECOMMENDATIONS; DIAGNOSIS; GUIDELINES; SELECTION; SURVIVAL; PATTERN;
D O I
10.1177/1352458519854162
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Brain magnetic resonance imaging (MRI) is the most effective surveillance tool for the detection of asymptomatic progressive multifocal leukoencephalopathy (PML). However, the optimal frequency for routine MRI surveillance is under-investigated. Objective: To understand whether, upon their first MRI appearance, PML lesions present a difference in volume when comparing patients who frequently underwent MRI surveillance (3/4 months) with those who were assessed at longer intervals (6/12 months) and to understand the impact of the volume of lesions on clinical outcome. Methods: The data of patients included in the Italian PML cohort were retrospectively analysed. Patients who had all the pre-diagnostic MRI scans available (n = 37) were included. The volume of PML lesion was calculated by manually outlining the PML lesion. Results: Compared with patients who underwent MRI examination at least every 4 months, patients who were assessed less frequently had a lesion of significantly higher volume (median: 2567 (883-3583) vs. 664 mm(3)(392-963)p = 0.006) and suffered a higher rate of disability (median: 2.25 expanded disability status scale points (-2.5 to 8) vs. 0.5 (-1 to 2.5)p = 0.004). Conclusion: The positive clinical outcome of patients undergoing frequent MRI surveillance and the small volume of the PML lesion upon first appearance justify a frequent surveillance using MRI in patients at high risk of PML.
引用
收藏
页码:1227 / 1236
页数:10
相关论文
共 40 条
  • [1] Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
    Austin, Peter C.
    [J]. STATISTICS IN MEDICINE, 2009, 28 (25) : 3083 - 3107
  • [2] Value of MRI as a surrogate marker for PML in natalizumab long-term therapy
    Ayzenberg, I.
    Lukas, C.
    Trampe, N.
    Gold, R.
    Hellwig, K.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 (08) : 1732 - 1733
  • [3] Classifying PML risk with disease modifying therapies
    Berger, Joseph R.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 12 : 59 - 63
  • [4] PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section
    Berger, Joseph R.
    Aksamit, Allen J.
    Clifford, David B.
    Davis, Larry
    Koralnik, Igor J.
    Sejvar, James J.
    Bartt, Russell
    Major, Eugene O.
    Nath, Avindra
    [J]. NEUROLOGY, 2013, 80 (15) : 1430 - 1438
  • [5] NATALIZUMAB-ASSOCIATED PML IDENTIFIED IN THE PRESYMPTOMATIC PHASE USING MRI SURVEILLANCE
    Blair, Nicholas F.
    Brew, Bruce J.
    Halpern, Jean-Pierre
    [J]. NEUROLOGY, 2012, 78 (07) : 507 - 508
  • [6] Subjective recollection independent from multifeatural context retrieval following damage to the posterior parietal cortex
    Ciaramelli, Elisa
    Faggi, Giorgia
    Scarpazza, Cristina
    Mattioli, Flavia
    Spaniol, Julia
    Ghetti, Simona
    Moscovitch, Morris
    [J]. CORTEX, 2017, 91 : 114 - 125
  • [7] Best practice recommendations for the selection and management of patients with multiple sclerosis receiving natalizumab therapy
    Coyle, Patricia K.
    Foley, John F.
    Fox, Edward J.
    Jeffery, Douglas R.
    Munschauer, Frederick E., III
    Tornatore, Carlo
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2009, 15 : S26 - S36
  • [8] Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
    Dong-Si, Tuan
    Richman, Sandra
    Wattjes, Mike P.
    Wenten, Made
    Gheuens, Sarah
    Philip, Jeffrey
    Datta, Shoibal
    McIninch, James
    Bozic, Carmen
    Bloomgren, Gary
    Richert, Nancy
    [J]. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2014, 1 (10): : 755 - 764
  • [9] High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - NO
    Enzinger, Christian
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (06) : 767 - 770
  • [10] Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging
    Hodel, Jerome
    Outteryck, Olivier
    Dubron, Celine
    Dutouquet, Bastien
    Benadjaoud, Mohamed Amine
    Duhin, Emeline
    Verclytte, Sebastien
    Zins, Marc
    Luciani, Alain
    Rahmouni, Alain
    Pruvo, Jean-Pierre
    Vermersch, Patrick
    Leclerc, Xavier
    [J]. RADIOLOGY, 2016, 278 (03) : 863 - 872